USA - NASDAQ:CDT - US20678X3044 - Common Stock
The current stock price of CDT is 2.46 USD. In the past month the price decreased by -52.62%. In the past year, price decreased by -99.81%.
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| TMO | THERMO FISHER SCIENTIFIC INC | 25.27 | 213.72B | ||
| DHR | DANAHER CORP | 27.32 | 150.85B | ||
| BRKRP | BRUKER CORP - BRKR 6 3/8 09/01/28 | 156.65 | 47.53B | ||
| A | AGILENT TECHNOLOGIES INC | 27.06 | 41.81B | ||
| IQV | IQVIA HOLDINGS INC | 18.13 | 35.85B | ||
| MTD | METTLER-TOLEDO INTERNATIONAL | 35.2 | 29.66B | ||
| WAT | WATERS CORP | 29.23 | 22.09B | ||
| WST | WEST PHARMACEUTICAL SERVICES | 38.94 | 19.80B | ||
| ILMN | ILLUMINA INC | 27.78 | 18.61B | ||
| MEDP | MEDPACE HOLDINGS INC | 41.41 | 16.63B | ||
| TEM | TEMPUS AI INC | N/A | 12.52B | ||
| ICLR | ICON PLC | 12.13 | 12.44B |
CDT Equity Inc is a US-based company operating in Life Sciences Tools & Services industry. The company is headquartered in Naples Florida, Florida and currently employs 6 full-time employees. The company went IPO on 2022-02-03. CDT Equity Inc., formerly Conduit Pharmaceuticals, Inc. is a data-driven biotech development company focused on identifying, enhancing, and advancing high-potential therapeutic assets through scientific innovation and strategic partnerships. Through advanced co-crystallization and solidform technologies developed at its Cambridge facility, it is engaged in improving drug properties and has helped in extending the patent life of certain drugs by up to 20 years. Its pipeline includes candidates targeting inflammatory and autoimmune disorders, as well as idiopathic male infertility, dermatology and animal health. The company applies proprietary algorithms utilizing AI-powered disease mapping to identify novel repurposing opportunities against a database of over 800 disease signatures. In addition, the Company has initiated pre-clinical in-vitro models to explore new indications, guided by AI-insights without human intervention.
CDT EQUITY INC
4851 Tamiami Trail North, Suite 200
Naples Florida FLORIDA US
Employees: 6
Phone: 16464919132
CDT Equity Inc is a US-based company operating in Life Sciences Tools & Services industry. The company is headquartered in Naples Florida, Florida and currently employs 6 full-time employees. The company went IPO on 2022-02-03. CDT Equity Inc., formerly Conduit Pharmaceuticals, Inc. is a data-driven biotech development company focused on identifying, enhancing, and advancing high-potential therapeutic assets through scientific innovation and strategic partnerships. Through advanced co-crystallization and solidform technologies developed at its Cambridge facility, it is engaged in improving drug properties and has helped in extending the patent life of certain drugs by up to 20 years. Its pipeline includes candidates targeting inflammatory and autoimmune disorders, as well as idiopathic male infertility, dermatology and animal health. The company applies proprietary algorithms utilizing AI-powered disease mapping to identify novel repurposing opportunities against a database of over 800 disease signatures. In addition, the Company has initiated pre-clinical in-vitro models to explore new indications, guided by AI-insights without human intervention.
The current stock price of CDT is 2.46 USD.
CDT does not pay a dividend.
CDT has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
CDT stock is listed on the Nasdaq exchange.
CDT EQUITY INC (CDT) has a market capitalization of 3.32M USD. This makes CDT a Nano Cap stock.
You can find the ownership structure of CDT EQUITY INC (CDT) on the Ownership tab.
ChartMill assigns a fundamental rating of 1 / 10 to CDT. CDT may be in some trouble as it scores bad on both profitability and health.
Over the last trailing twelve months CDT reported a non-GAAP Earnings per Share(EPS) of -1350.43. The EPS decreased by -16780.37% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -250.86% | ||
| ROE | -567.89% | ||
| Debt/Equity | 0.53 |